EP3801221A4 - Methods of delaying and reversing alzheimer's disease progression - Google Patents
Methods of delaying and reversing alzheimer's disease progression Download PDFInfo
- Publication number
- EP3801221A4 EP3801221A4 EP19819198.3A EP19819198A EP3801221A4 EP 3801221 A4 EP3801221 A4 EP 3801221A4 EP 19819198 A EP19819198 A EP 19819198A EP 3801221 A4 EP3801221 A4 EP 3801221A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- delaying
- methods
- disease progression
- reversing alzheimer
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
- A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
- A61B5/0042—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/15—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced iron-sulfur protein as one donor, and incorporation of one atom of oxygen (1.14.15)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862683587P | 2018-06-11 | 2018-06-11 | |
PCT/US2019/036395 WO2019241156A1 (en) | 2018-06-11 | 2019-06-10 | Methods of delaying and reversing alzheimer's disease progression |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3801221A1 EP3801221A1 (en) | 2021-04-14 |
EP3801221A4 true EP3801221A4 (en) | 2022-03-30 |
Family
ID=68842290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19819198.3A Withdrawn EP3801221A4 (en) | 2018-06-11 | 2019-06-10 | Methods of delaying and reversing alzheimer's disease progression |
Country Status (3)
Country | Link |
---|---|
US (1) | US20210322386A1 (en) |
EP (1) | EP3801221A4 (en) |
WO (1) | WO2019241156A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024400A1 (en) * | 1997-11-10 | 1999-05-20 | Vyrex Corporation | Probucol esters and uses thereof |
WO2005058842A1 (en) * | 2003-12-15 | 2005-06-30 | Laboratoire Theramex | 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150031655A1 (en) * | 2011-04-15 | 2015-01-29 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
US20150005351A1 (en) * | 2013-06-26 | 2015-01-01 | Loma Linda University | Methods and kits for determining risk for developing alzheimer's disease and prevention or treatment thereof |
AU2017371071B2 (en) * | 2016-12-09 | 2023-06-15 | Loma Linda University Health | Methods of diagnosing Alzheimer's disease and risk of progression to Alzheimer's disease |
-
2019
- 2019-06-10 WO PCT/US2019/036395 patent/WO2019241156A1/en unknown
- 2019-06-10 US US17/250,185 patent/US20210322386A1/en active Pending
- 2019-06-10 EP EP19819198.3A patent/EP3801221A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024400A1 (en) * | 1997-11-10 | 1999-05-20 | Vyrex Corporation | Probucol esters and uses thereof |
WO2005058842A1 (en) * | 2003-12-15 | 2005-06-30 | Laboratoire Theramex | 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them |
Non-Patent Citations (4)
Title |
---|
CATHERINE M BENDER ET AL: "Patterns of change in cognitive function with anastrozole therapy", CANCER, AMERICAN CANCER SOCIETY , PHILADELPHIA , PA, US, vol. 121, no. 15, 23 April 2015 (2015-04-23), pages 2627 - 2636, XP071127891, ISSN: 0008-543X, DOI: 10.1002/CNCR.29393 * |
GABRIELLA TESTA ET AL: "Changes in brain oxysterols at different stages of Alzheimer's disease: Their involvement in neuroinflammation", REDOX BIOLOGY, vol. 10, 16 September 2016 (2016-09-16), NL, pages 24 - 33, XP055423027, ISSN: 2213-2317, DOI: 10.1016/j.redox.2016.09.001 * |
See also references of WO2019241156A1 * |
ZHANG XIAONA ET AL: "Increased Levels of 27-Hydroxycholesterol Induced by Dietary Cholesterol in Brain Contribute to Learning and Memory Impairment in Rats", MOLECULAR NUTRITION & FOOD RESEARCH, vol. 62, no. 3, 2 January 2018 (2018-01-02), DE, pages 1700531, XP055891689, ISSN: 1613-4125, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fmnfr.201700531> DOI: 10.1002/mnfr.201700531 * |
Also Published As
Publication number | Publication date |
---|---|
EP3801221A1 (en) | 2021-04-14 |
US20210322386A1 (en) | 2021-10-21 |
WO2019241156A1 (en) | 2019-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3619308A4 (en) | Compositions and methods of treating huntington's disease | |
AU2016255474B2 (en) | Application of PI4KIIIα protein and related membrane protein complex in treating Alzheimer's disease | |
EP3917564A4 (en) | Anti-claudin 18 antibodies and methods of use thereof | |
EP3633034A4 (en) | MODIFIED Cas9 PROTEIN AND USE THEREOF | |
EP3579827A4 (en) | Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease | |
IL280315A (en) | Methods of treatment and prevention of alzheimer's disease | |
EP3458036A4 (en) | Methods of treating or preventing alzheimer's disease and associated conditions | |
EP3891175A4 (en) | Modified proteins and associated methods of treatment | |
EP3835418A4 (en) | Novel crispr-associated protein and use thereof | |
EP3969125A4 (en) | Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases | |
EP3678701A4 (en) | Therapeutic protein compositions and methods of making and using the same | |
EP3972646A4 (en) | Apohemoglobin-haptoglobin complexes and methods of using thereof | |
EP3805386A4 (en) | Modified cas9 protein and use thereof | |
EP3806845A4 (en) | Cannabinoid composition and methods of treatment using the same | |
EP3805253A4 (en) | Mutant of human papillomavirus type 39 l1 protein | |
EP3731867A4 (en) | Anti-lrp5/6 antibodies and methods of use | |
EP3347486A4 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
EP3684388A4 (en) | Compositions and methods of treating huntington's disease | |
EP3820492A4 (en) | Apmv and uses thereof for the treatment of cancer | |
EP3913002A4 (en) | Application of ecm1 in prevention and/or treatment of liver fibrosis-related diseases | |
EP3820482A4 (en) | Tumor reduction formulations and methods of use thereof | |
EP3765485A4 (en) | Immuno-exosomes and methods of use thereof | |
EP3761989A4 (en) | Imidazodiazepinediones and methods of use thereof | |
EP3982819A4 (en) | Methods for evaluation and treatment of alzheimer's disease and applications thereof | |
EP3852722A4 (en) | Compositions and methods for the treatment of parkinson's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210111 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61B0005000000 Ipc: A61K0031419600 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220224 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12Q 1/68 20180101ALI20220220BHEP Ipc: C07K 14/47 20060101ALI20220220BHEP Ipc: A61B 5/00 20060101ALI20220220BHEP Ipc: A61P 25/28 20060101ALI20220220BHEP Ipc: A61K 31/4196 20060101AFI20220220BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20220927 |